155 related articles for article (PubMed ID: 22043047)
1. kConFab: a familial breast cancer consortium facilitating research and translational oncology.
Thorne H; Mitchell G; Fox S;
J Natl Cancer Inst Monogr; 2011; 2011(43):79-81. PubMed ID: 22043047
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA
J Clin Oncol; 2012 Jan; 30(1):19-26. PubMed ID: 22147742
[TBL] [Abstract][Full Text] [Related]
3. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.
Hopper JL; Southey MC; Dite GS; Jolley DJ; Giles GG; McCredie MR; Easton DF; Venter DJ
Cancer Epidemiol Biomarkers Prev; 1999 Sep; 8(9):741-7. PubMed ID: 10498392
[TBL] [Abstract][Full Text] [Related]
4. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer risks for BRCA1/2 carriers.
Wacholder S; Struewing JP; Hartge P; Greene MH; Tucker MA
Science; 2004 Dec; 306(5705):2187-91; author reply 2187-91. PubMed ID: 15622558
[No Abstract] [Full Text] [Related]
6. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.
Rennert G; Bisland-Naggan S; Barnett-Griness O; Bar-Joseph N; Zhang S; Rennert HS; Narod SA
N Engl J Med; 2007 Jul; 357(2):115-23. PubMed ID: 17625123
[TBL] [Abstract][Full Text] [Related]
7. Cancer risks for Australian women with a BRCA1 or a BRCA2 mutation.
Suthers GK
ANZ J Surg; 2007 May; 77(5):314-9. PubMed ID: 17497966
[TBL] [Abstract][Full Text] [Related]
8. Considerations in genetic counseling for inherited breast cancer predisposition.
Robson ME; Offit K
Semin Radiat Oncol; 2002 Oct; 12(4):362-70. PubMed ID: 12382194
[TBL] [Abstract][Full Text] [Related]
9. Can genetic testing guide treatment in breast cancer?
Tutt A; Ashworth A
Eur J Cancer; 2008 Dec; 44(18):2774-80. PubMed ID: 19027287
[TBL] [Abstract][Full Text] [Related]
10. Hereditary breast cancer: from bench to bedside.
De Grève J; Sermijn E; De Brakeleer S; Ren Z; Teugels E
Curr Opin Oncol; 2008 Nov; 20(6):605-13. PubMed ID: 18841041
[TBL] [Abstract][Full Text] [Related]
11. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
12. Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).
Kiely BE; Jenkins MA; McKinley JM; Friedlander ML; Weideman P; Milne RL; McLachlan SA; Hopper JL; Phillips KA
Breast Cancer Res Treat; 2010 Apr; 120(3):715-23. PubMed ID: 19669874
[TBL] [Abstract][Full Text] [Related]
13. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P
Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400
[TBL] [Abstract][Full Text] [Related]
14. BRCA1 and BRCA2: 1994 and beyond.
Narod SA; Foulkes WD
Nat Rev Cancer; 2004 Sep; 4(9):665-76. PubMed ID: 15343273
[TBL] [Abstract][Full Text] [Related]
15. The prevention of hereditary breast cancer.
Rodriquez E; Domchek SM
Semin Oncol; 2007 Oct; 34(5):401-5. PubMed ID: 17920894
[TBL] [Abstract][Full Text] [Related]
16. [PARP inhibitors: new therapeutic agents in breast and ovarian cancer].
Mercier-Vogel L; Bodmer A; Castiglione M
Rev Med Suisse; 2011 May; 7(296):1137-40. PubMed ID: 21721203
[TBL] [Abstract][Full Text] [Related]
17. [Molecular basis of breast cancer related to BRCA 1 and BRCA2 genes: characteristics and targeting therapy].
Levanat S; Cvok ML
Lijec Vjesn; 2010; 132(1-2):34-7. PubMed ID: 20359158
[TBL] [Abstract][Full Text] [Related]
18. Choices--and uncertainties--for women with BRCA mutations.
Couzin J
Science; 2003 Oct; 302(5645):592. PubMed ID: 14576419
[No Abstract] [Full Text] [Related]
19. Bias in intervention studies that enroll patients from high-risk clinics.
Wacholder S
J Natl Cancer Inst; 2004 Aug; 96(16):1204-7. PubMed ID: 15316055
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians.
Peshkin BN; Isaacs C; Finch C; Kent S; Schwartz MD
J Clin Oncol; 2003 Dec; 21(23):4322-8. PubMed ID: 14645421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
